Associated Papers
The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies.
Laface C et al.
Pharmaceutics, 2023
ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling - a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial.
Kringelbach T et al.
Bmc Cancer, 2023
ERBB family fusions are recurrent and actionable oncogenic targets across cancer types.
Schubert L et al.
Frontiers in Oncology, 2023
Assessment of aggressive bladder cancer mutations in plasma cell-free DNA.
Carrasco R et al.
Frontiers in Oncology, 2023
Molecular target therapeutics of EGF-TKI and downstream signaling pathways in non-small cell lung cancers.
Liu CY et al.
Journal of the Chinese Medical Association : Jcma, 2022
Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model.
Ikeuchi H et al.
Oncogene, 2022
Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity.
Hong TH et al.
Journal for Immunotherapy of Cancer, 2020
Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario.
Russo A et al.
International Journal of Molecular Sciences, 2019
Molecular characterization of circulating colorectal tumor cells defines genetic signatures for individualized cancer care.
Kong SL et al.
Oncotarget, 2017
BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations.
Deihimi S et al.
Oncotarget, 2017
Epidermal growth factor receptor tyrosine kinase inhibitors with conventional chemotherapy for the treatment of non-small cell lung cancer.
Gao Y et al.
Oncotargets and Therapy, 2016
Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure.
Cho KM et al.
The Korean Journal of Internal Medicine, 2015
Genetic Polymorphism, Telomere Biology and Non-Small Lung Cancer Risk.
Wei R et al.
Journal of Genetics and Genomics = Yi Chuan Xue Bao, 2015
Discrimination of driver and passenger mutations in epidermal growth factor receptor in cancer.
Anoosha P et al.
Mutation Research, 2015
The impact of rare EGFR mutations on the treatment response of patients with non-small cell lung cancer.
Karachaliou N et al.
Expert Review of Respiratory Medicine, 2015
Global connectivity of hub residues in Oncoprotein structures encodes genetic factors dictating personalized drug response to targeted Cancer therapy.
Soundararajan V et al.
Scientific Reports, 2014
Assessment of computational methods for predicting the effects of missense mutations in human cancers.
Gnad F et al.
Bmc Genomics, 2013
Oncogenic potential is related to activating effect of cancer single and double somatic mutations in receptor tyrosine kinases.
Hashimoto K et al.
Human Mutation, 2012
Impact of smoking status and pathologic type on epidermal growth factor receptor mutations in lung cancer.
Huang YS et al.
Chinese Medical Journal, 2011
Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status.
Onitsuka T et al.
Lung Cancer (amsterdam, Netherlands), 2010
Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations.
Tam IY et al.
Molecular Cancer Therapeutics, 2009
Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations.
Sugio K et al.
Lung Cancer (amsterdam, Netherlands), 2009
Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity.
Tang Z et al.
Oncogene, 2009
Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.
Kancha RK et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2009
Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern.
Wu SG et al.
The Oncologist, 2008
Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer.
Wong AS et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2008
Epidemiology of doublet/multiplet mutations in lung cancers: evidence that a subset arises by chronocoordinate events.
Chen Z et al.
Plos One, 2008
Erlotinib response of EGFR-mutant gefitinib-resistant non-small-cell lung cancer.
Chang JW et al.
Lung Cancer (amsterdam, Netherlands), 2007
Epidermal growth factor receptor double activating mutations involving both exons 19 and 21 exist in Chinese non-small cell lung cancer patients.
Zhang GC et al.
Clinical Oncology (royal College of Radiologists (great Britain)), 2007
EGFR kinase domain mutations - functional impact and relevance for lung cancer therapy.
Irmer D et al.
Oncogene, 2007
Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway.
Rosell R et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2006
Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer.
Ahmed SM et al.
Respirology (carlton, Vic.), 2006
[Relationship of the curative effects of gefitinib on non-small cell lung carcinoma to gender and to epithelial growth factor receptor status].
Xu CR et al.
Zhonghua Yi Xue Za Zhi, 2006
Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation.
Choong NW et al.
Nature Clinical Practice. Oncology, 2006
A new mechanism for primary resistance to gefitinib in lung adenocarcinoma: the role of a novel G796A mutation in exon 20 of EGFR.
Uramoto H et al.
Anticancer Research, 0
Genomic characterization of recurrent high-grade astroblastoma.
Bale TA et al.
Cancer Genetics, 0